Guía de Práctica Clínica sobre Cuidados Paliativos - GuíaSalud
Guía de Práctica Clínica sobre Cuidados Paliativos - GuíaSalud
Guía de Práctica Clínica sobre Cuidados Paliativos - GuíaSalud
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
154. Ioannidis JP, Hesketh PJ, Lau J. Contribution of <strong>de</strong>xamethasone to control of<br />
chemotherapy-induced nausea and vomiting: a meta-analysis of randomized<br />
evi<strong>de</strong>nce. J Clin Oncol. 2000;18(19):3409-22.<br />
155. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases.<br />
Clinical Evi<strong>de</strong>nce. London: BMJ Publishing Group; 2007. p. 1-12.<br />
156. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies<br />
comparing 5-HT3 receptor antagonists to conventional anti-emetics in the<br />
prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer.<br />
1997;33(1):66-74.<br />
157. Poli-Bigelli S, Rodrigues-Pereira J, Cari<strong>de</strong>s AD, Julie MG, Eldridge K, Hipple<br />
A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard<br />
antiemetic therapy improves control of chemotherapy-induced nausea and<br />
vomiting. Results from a randomized, double-blind, placebo-controlled trial in<br />
Latin America. Cancer. 2003;97(12):3090-8.<br />
158. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ.<br />
Cannabinoids for control of chemotherapy induced nausea and vomiting:<br />
quantitative systematic review. BMJ. 2001;323(7303):16-21.<br />
159. Tramer MR, Reynolds DJ, Stoner NS, Moore RA, McQuay HJ. Efficacy of<br />
5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a<br />
quantitative systematic review. Eur J Cancer. 1998;34(12):1836-44.<br />
160. Supportive Care �� Symptom Control Regimens. Management of Chemotherapy-induced<br />
Nausea and Vomiting. Disponible en http://www cancercare on<br />
ca/pdfchemo/NVgui<strong>de</strong>lines pdf [accedido en: septiembre 2007]<br />
161. Hoskin P. Radiotherapy in symptom management. In: Doyle D, Hanks G,<br />
Chreney N, Calman K, editors. Oxford Textbook of Palliative Medicine. Third<br />
ed. Oxford: Oxford University Press; 2004. p. 239-59.<br />
162. Cancer care Ontario Practice Gui<strong>de</strong>lines Initiative. Use of 5-HT 3 receptor antagonists<br />
in patients receiving mo<strong>de</strong>rately or highly emetogenic chemotherapy.<br />
Disponible en: www cancercare on ca/ [accedido en: septiembre 2007] 2003<br />
163. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review<br />
of the efficacy of antiemetics in the treatment of nausea in patients with faradvanced<br />
cancer. Support Care Cancer. 2004;12(6):432-40.<br />
164. Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, et al.<br />
Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative<br />
patient: A systematic review [3]. Journal of Pain �� Symptom Management.<br />
2001;22(2):631-4.<br />
165. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support<br />
Care Cancer. 2005;13(2):117-21.<br />
166. Ahmedzai SH, Boland j. Constipation in people prescribed opioids. In: BMJ<br />
Publishing Group, editor. Clinical Evi<strong>de</strong>nce. London: 2007. p. 2407.<br />
188 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS
Change language